UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2020
Harpoon Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-38800 | 47-3458693 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 131 Oyster Point Blvd, Suite 300 South San Francisco, California |
94080 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(650) 443-7400
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common stock, par value $0.0001 per share | HARP | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This amendment to the Current Report on Form 8-K filed on April 1, 2020 (the “Original 8-K”) is being filed to report the appointment of Andrew R. Robbins and Joseph S. Bailes to certain committees of the board of directors (the “Board”) of Harpoon Therapeutics, Inc., a Delaware corporation. No other changes are being made to any other disclosure contained in the Original 8-K.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 14, 2020, Mr. Robbins was appointed to the Audit Committee of the Board (the “Audit Committee”) and the Compensation Committee of the Board (the “Compensation Committee”), and Dr. Bailes was appointed to the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”). As a result of these appointments and other committee-membership changes approved by the Board, the Audit Committee is now comprised of Ms. Eastland and Messrs. Myers and Robbins, the Compensation Committee is now comprised of Messrs. Evnin, Hunt, Myers and Robbins, and the Nominating Committee is now comprised of Ms. Eastland and Messrs. Bailes, Drachman and Myers. The Board also appointed Mr. Hunt as Chairman of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARPOON THERAPEUTICS, INC. | ||
| By: | /s/ Gerald McMahon, Ph.D. | |
| Gerald McMahon, Ph.D. President and Chief Executive Officer | ||
Dated: April 17, 2020